Background: People who inject drugs (PWID) represent a key population disproportionately affected by blood-borne viruses. Updated epidemiological data are crucial for informing public health interventions. This study provides a 2024 update on the seroprevalence and correlates of Hepatitis B (HBV), Hepatitis C (HCV), and Human Immunodeficiency Virus (HIV) among PWID at Kuwait’s national addiction treatment center, building on a previous 2017 baseline. Methods: A cross-sectional study was conducted from January to December 2024, enrolling 1,287 consecutive patients. Serological screening for HBsAg, anti-HCV, and anti-HIV was performed using chemiluminescent immunoassays. Seropositive samples underwent confirmatory nucleic acid testing to detect active viremia. Multivariable logistic regression was used to identify factors associated with each infection. Results: The cohort was predominantly male (86.6%) and Kuwaiti (87.3%), with a median age of 33 years. The overall seroprevalence was 0.2% for HBsAg (2/1,255), 2.1% for anti-HCV (25/1,169), and 0.93% for anti-HIV (12/1,287). A significant age-dependent increase in HCV prevalence was observed ( p < 0.001), with the highest prevalence (10.8%) in participants aged ≥ 50 years. All HIV-positive cases were male. Molecular testing revealed universal active viremia for HCV (100%, 25/25) and HBV (100%, 2/2), and detectable viremia in 66.7% (8/12) of HIV-seropositive cases. In multivariable analysis, increasing age was significantly associated with HCV infection (aOR = 1.1, 95% CI: 1.07–1.16, p < 0.001). For HIV, female sex was associated with significantly lower odds of infection (aOR = 0.14, 95% CI: 0.02–0.92, p = 0.04). Due to the extremely low number of HBV-reactive cases ( n = 2), multivariable logistic regression was not feasible for HBV, and no adjusted estimates could be derived. Conclusion: Compared to 2017 data, this study reveals a concerning increase in HIV prevalence and a shift to universal active HCV viremia among PWID in Kuwait. The near-ubiquitous presence of transmissible infection upon seroconversion indicates a critical gap in the care cascade. These findings underscore an urgent need for the scale-up of targeted harm reduction, test-and-treat strategies, and integrated care services to curb transmission.